The evolving concept of SLE comorbidities

References

• Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;35(11):2152–2158.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–2557.
   PubMed Web of Science ®Google Scholar
• Rees F, Doherty M, Grainge M, et al. Burden of comorbidity in systemic lupus erythematosus in the UK, 1999–2012. Arthritis Care Res (Hoboken). 2016;68(6):819–827.
   PubMed Web of Science ®Google Scholar
• Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, et al. Systemic lupus erythematosus and malignancies: a review article. Rheum Dis Clin North Am. 2014;40(3):497–506.
   PubMed Web of Science ®Google Scholar
• Baker K, Pope J, Fortin P, et al. Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. Lupus. 2009;18(14):1281–1288.
   PubMed Web of Science ®Google Scholar
• Alarcón GS. McGwin G Jr, Uribe Aet al.Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum. 2004;51(3):465–474.
   PubMed Web of Science ®Google Scholar
• Yang Y, Thumboo J, Earnest A, et al. The effect of comorbidity on hospital mortality in patients with SLE from an Asian tertiary hospital. Lupus. 2014;23(7):714–720.
   PubMed Web of Science ®Google Scholar
• Jönsen A, Clarke AE, Joseph L, et al. Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(9):1233–1237.
   PubMed Web of Science ®Google Scholar
• Ward MM, Pajevic S, Dreyfuss J, et al. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum. 2006;55(1):74–80.
   PubMed Web of Science ®Google Scholar
• Ording AG, Sørensen HT. Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs. Clin Epidemiol. 2013;5:199–203.
   PubMedGoogle Scholar
• Radner H, Yoshida K, Smolen JS, et al. Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat Rev Rheumatol. 2014;10(4):252–256.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–967.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the systemic lupusinternational collaborating clinics/american college of rheumatology damage index inpatients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–813.
   PubMed Web of Science ®Google Scholar
• ICD-9-CM. Official authorized addendum for the International Classification of Diseases, Ninth Revision, Clinical Modification. Volumes 1, 2, and 3. Effective for discharge October 1, 1988. National Center for Health Statistics and the Health Care Financing Administration. J Am Med Rec Assoc. 1988;59(8):suppl 1–34.
   Google Scholar
• Rúa-Figueroa I, de Castro MF, Andreu JL, et al. Comorbidities in patients with primary sjögren’s syndrome and systemic lupus erythematosus: a comparative registries-based study. Arthritis Care Res (Hoboken). 2017;69(1):38–45.
   PubMed Web of Science ®Google Scholar
• Hak AE, Karlson EW, Feskanich D, et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study. Arthritis Rheum. 2009;61(10):1396–1402.
   PubMed Web of Science ®Google Scholar
• Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42(2):338–346.
   PubMed Web of Science ®Google Scholar
• Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176(8):708–719.
   PubMed Web of Science ®Google Scholar
• Bengtsson C, Ohman ML, Nived O, et al. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus. 2012;21(4):452–459.
   PubMed Web of Science ®Google Scholar
• Toloza SM, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004;50(12):3947–3957.
   PubMed Web of Science ®Google Scholar
• Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93(5):513–519.
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–415.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34(1):70–75.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman DD, Anderson NM, et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med. 2016;3(1):e000143.
   PubMedGoogle Scholar
• Cramarossa G, Urowitz MB, Su J, et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus. 2017;26(4):365–372.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308.
   PubMed Web of Science ®Google Scholar
• Kasturi S, Sammaritano LR. Corticosteroids in Lupus. Rheum Dis Clin North Am. 2016;42(1):47–62.
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–1808.
   PubMed Web of Science ®Google Scholar
• Calvo-Alén J, McGwin G, Toloza S, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis. 2006;65(6):785–790.
   PubMed Web of Science ®Google Scholar
• Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014;41(4):680–687.
   PubMed Web of Science ®Google Scholar
• Chan PC, Yu CH, Yeh KW, et al. Comorbidities of pediatric systemic lupus erythematosus: a 6-year nationwide population-based study. J Microbiol Immunol Infect. 2016;49(2):257–263.
   PubMedGoogle Scholar
• Urowitz M, Gladman DD, Anderson N, et al. The Systemic Lupus International Collaborating Clinics (SLICC) Group. Accrual of disease comorbidities over 8 years in a multicentre inception SLE cohort [abstract]. Arthritis Rheumatol. 2016;68(suppl):10.
   Google Scholar
• Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399–2406.
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407–2415.
   PubMed Web of Science ®Google Scholar
• Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE–mechanisms and management. Nat Rev Rheumatol. 2012;8(4):214–223.
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331–2337.
   PubMed Web of Science ®Google Scholar
• Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol. 2013;62(3):255–262.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman D, Ibañez D, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6):881–887.
   PubMed Web of Science ®Google Scholar
• Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77–95.
   PubMed Web of Science ®Google Scholar
• Kim CH, Al-Kindi SG, Jandali B, et al. Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2017;103(3):227–233.
   PubMed Web of Science ®Google Scholar
• Krishnan E. Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med. 2005;118(12):1415.
   PubMedGoogle Scholar
• Zöller B, Li X, Sundquist J, et al. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol. 2012;12:41.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, To CH. Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. Scand J Rheumatol. 2009;38(5):362–368.
   PubMed Web of Science ®Google Scholar
• Chuang YW, Yu MC, Lin CL, et al. Risk of peripheral arterial occlusive disease in patients with systemic lupus erythematosus: a nationwide population-based cohort study. Medicine (Baltimore). 2015;94(46):e2121.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Criqui MH, Treat-Jacobsen D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–1324.
   PubMed Web of Science ®Google Scholar
• Erdozain JG, Villar I, Nieto J, et al. Peripheral arterial disease in systemic lupus erythematosus: prevalence and risk factors. J Rheumatol. 2014;41(2):310–317.
   PubMed Web of Science ®Google Scholar
• Ramos R, Quesada M, Solanas P, et al. REGICOR Investigators. Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. Eur J Vasc Endovasc Surg. 2009;38(3):305–311.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221–225.
   PubMed Web of Science ®Google Scholar
• Björnådal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol. 2004;31(4):713–719.
   PubMed Web of Science ®Google Scholar
• Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25(7):727–734.
   PubMed Web of Science ®Google Scholar
• Yurkovich M, Vostretsova K, Chen W, et al. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2014;66(4):608–616.
   PubMed Web of Science ®Google Scholar
• Petri M, Spence D, Bone LR, et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore). 1992;71(5):291–302.
   PubMed Web of Science ®Google Scholar
• Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016;28(5):497–505.
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 2004;50(3):849–857.
   PubMed Web of Science ®Google Scholar
• Ghaussy NO, Sibbitt W Jr, Bankhurst AD, et al. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol. 2003;30(6):1215–1221.
   PubMed Web of Science ®Google Scholar
• Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol. 1998;25(9):1716–1719.
   PubMed Web of Science ®Google Scholar
• Bertoli AM, Vilá LM, Alarcón GS, et al. Factors associated with arterial vascular events in PROFILE: a multiethnic lupus cohort. Lupus. 2009;18(11):958–965.
   PubMed Web of Science ®Google Scholar
• Kiani AN, Post WS, Magder LS, et al. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50(11):2071–2079.
   PubMed Web of Science ®Google Scholar
• Burgos PI. McGwin G Jr, Reveille JD, et al.. Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology (Oxford). 2010;49(9):1720–1725.
   PubMed Web of Science ®Google Scholar
• Gustafsson JT, Simard JF, Gunnarsson I, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14(2):R46.
   PubMed Web of Science ®Google Scholar
• Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest. 2007;131(5):1557–1566.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman D, Ibañez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731–735.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the toronto risk factor study. Arthritis Rheum. 2003;48(11):3159–3167.
   PubMed Web of Science ®Google Scholar
• Chaiamnuay S, Bertoli AM, Roseman JM, et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis. 2007;66(5):618–622.
   PubMed Web of Science ®Google Scholar
• Tselios K, Koumaras C, Urowitz MB, et al. Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. Semin Arthritis Rheum. 2014;43(4):521–525.
   PubMed Web of Science ®Google Scholar
• Fernández-Nebro A, Rúa-Figueroa Í, López-Longo FJ, et al. Cardiovascular events in systemic lupus erythematosus: a nationwide study in spain from the RELESSER registry. Medicine (Baltimore). 2015;94(29):e1183.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Ibañez D, et al. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. Rheumatology (Oxford). 2012;51(3):528–534.
   PubMed Web of Science ®Google Scholar
• Nikpour M, Urowitz MB, Ibañez D, et al. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther. 2011;13(5):R156.
   PubMed Web of Science ®Google Scholar
• Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol. 2010;37(2):322–329.
   PubMed Web of Science ®Google Scholar
• Tselios K, Sheane BJ, Gladman DD, et al. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: a systematic review. J Rheumatol. 2016;43(1):54–65.
   PubMed Web of Science ®Google Scholar
• Mikdashi J, Handwerger B, Langenberg P, et al. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007;38(2):281–285.
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol. 2006;33(12):2458–2463.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
   PubMed Web of Science ®Google Scholar
• Durán-Barragán S. McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus—results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47(7):1093–1096.
   PubMed Web of Science ®Google Scholar
• Tselios K, Koumaras C, Gladman DD, et al. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45(5):604–610.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman D, Ibañez D, et al. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum. 2008 15;59(2):176–180.
   PubMed Web of Science ®Google Scholar
• Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus. 1997;6(6):533–539.
   PubMed Web of Science ®Google Scholar
• Ballocca F, D’Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(11):1435–1441.
   PubMed Web of Science ®Google Scholar
• Wang XY, Tang XQ, Huang YJ, et al. Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2012;31(4):669–675.
   PubMed Web of Science ®Google Scholar
• Eder L, Gladman DD, Ibañez D, et al. The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients. Lupus. 2014;23(11):1142–1148.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz MB, Gladman DD, et al. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 1999;26(10):2137–2143.
   PubMed Web of Science ®Google Scholar
• Bruce I. Lupus: the new diabetes. SLE and chronic disease management. Lupus. 2013;22(12):1203–1204.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEPT) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
   PubMed Web of Science ®Google Scholar
• Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285–296.
   PubMed Web of Science ®Google Scholar
• Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011;70(5):760–765.
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhao X, Xie H, et al. Efficacy and safety of statins in the prevention of atherosclerosis in patients with systemic lupus erythematosus–a meta-analysis of randomized controlled trials. Int J Cardiol. 2013;167(1):301–303.
   PubMed Web of Science ®Google Scholar
• Soubrier M, Mathieu S, Hermet M, et al. Do all lupus patients need statins? Joint Bone Spine. 2013;80(3):244–249.
   PubMed Web of Science ®Google Scholar
• Yu HH, Chen PC, Yang YH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. Atherosclerosis. 2015;243(1):11–18.
   PubMed Web of Science ®Google Scholar
• McMahon M, Skaggs BJ, Grossman JM, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol. 2014;66(1):130–139.
   PubMed Web of Science ®Google Scholar
• Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol. 2008;35(7):1300–1306.
   PubMed Web of Science ®Google Scholar
• Andrade RM, Alarcón GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Fut Rheumatol. 2006;1(2):225–233.
   Google Scholar
• Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5(Suppl1):S16–22.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2013;2013(36 Suppl 1):S11–66.
   Web of Science ®Google Scholar
• Katz P, Gregorich S, Yazdany J, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(2):261–268.
   PubMed Web of Science ®Google Scholar
• Cypiene A, Kovaite M, Venalis A, et al. Arterial wall dysfunction in systemic lupus erythematosus. Lupus. 2009;18(6):522–529.
   PubMed Web of Science ®Google Scholar
• Schanberg LE, Sandborg C, Barnhart HX, et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum. 2009;60(5):1496–1507.
   PubMed Web of Science ®Google Scholar
• Souza AW, Hatta FS, Miranda F Jr, et al. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J. 2005;123(3):137–142.
   PubMedGoogle Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–38.
   PubMed Web of Science ®Google Scholar
• Davies RJ, Lomer MC, Yeo SI, et al. Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids. Lupus. 2012;21(6):649–655.
   PubMed Web of Science ®Google Scholar
• Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348(9035):1120–1124.
   PubMed Web of Science ®Google Scholar
• Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015;1:CD006612.
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, González LA, Zhang J, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford). 2009;48(7):817–822.
   PubMed Web of Science ®Google Scholar
• Burgos PI, Vilá LM, Reveille JD, et al. Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX). Lupus. 2009;18(14):1303–1308.
   PubMed Web of Science ®Google Scholar
• Gustafsson J, Gunnarsson I, Börjesson O, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther. 2009;11(6):R186.
   PubMed Web of Science ®Google Scholar
• Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42(1):51–60.
   PubMed Web of Science ®Google Scholar
• Frerix M, Stegbauer A, Kreuter A, et al. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplex sonography study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis Res Ther. 2014;16(1):R54.
   PubMed Web of Science ®Google Scholar
• Ibañez D, Gladman D, Urowitz M. Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J Rheumatol. 2007;34(2):336–340.
   PubMed Web of Science ®Google Scholar
• Bertoli AM, Alarcón GS, Calvo-Alén J, et al., LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical features, course, and outcome in patients with late-onset disease. Arthritis Rheum. 2006;54(5):1580–1587.
   PubMed Web of Science ®Google Scholar
• Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford). 2007;46(6):983–988.
   PubMed Web of Science ®Google Scholar
• Plazak W, Pasowicz M, Kostkiewicz M, et al. Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res. 2011;60(10):973–980.
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Andreoli L, Scanzi F, et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10–20.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Mellemkjaer L, Starklint H, et al. High risk of ischemic heart disease in patients with lupus nephritis. J Rheumatol. 2011;38(11):2400–2405.
   PubMed Web of Science ®Google Scholar
• Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000;9(3):170–175.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130–135.
   PubMed Web of Science ®Google Scholar
• Ni J, Qiu LJ, Hu LF, et al. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Lupus. 2014;23(3):284–292.
   PubMed Web of Science ®Google Scholar
• Cao L, Tong H, Xu G, et al. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One. 2015;10(4):e0122964.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Ramsey-Goldman R, Foulkes WD, et al. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer. 2011;104(9):1478–1481.
   PubMed Web of Science ®Google Scholar
• Goobie GC, Bernatsky S, Ramsey-Goldman R, et al. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol. 2015;27(5):454–460.
   PubMed Web of Science ®Google Scholar
• Lu M, Bernatsky S, Ramsey-Goldman R, et al. Non-lymphoma hematological malignancies in systemic lupus erythematosus. Oncology. 2013;85(4):235–240.
   PubMed Web of Science ®Google Scholar
• Apor E, O´Brien J, Stephen M, et al. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014;38(9):1067–1071.
   PubMed Web of Science ®Google Scholar
• Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol. 2011;7(6):360–368.
   PubMed Web of Science ®Google Scholar
• Wang SS, Vajdic CM, Linet MS, et al. Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. Am J Epidemiol. 2015;181(6):406–421.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138–142.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Lin MS, Su YJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2016;pii: kew457. [ Epub ahead of print]. 10.1093/rheumatology/kew457
   Web of Science ®Google Scholar
• Hemminki K, Liu X, Ji J, et al. Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Eur Respir J. 2012;40(6):1489–1495.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med. 2005;11(5):431–437.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008;67(1):74–79.
   PubMed Web of Science ®Google Scholar
• Dreyer L, Faurschou M, Mogensen M, et al. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2008;58(3):657–666.
   PubMed Web of Science ®Google Scholar
• Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev. 2014;13(7):730–735.
   PubMed Web of Science ®Google Scholar
• Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016;66(2):96–114.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, et al., For the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314.
   PubMed Web of Science ®Google Scholar
• Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, et al. Breast cancer in systemic lupus erythematosus. Oncology. 2013;85(2):117–121.
   PubMed Web of Science ®Google Scholar
• Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(1):2–8.
   PubMed Web of Science ®Google Scholar
• Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(7):2044–2050.
   PubMed Web of Science ®Google Scholar
• Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14(2):106–112.
   PubMedGoogle Scholar
• Bultink IE, Lems WF. Lupus and fractures. Curr Opin Rheumatol. 2016;28(4):426–432.
   PubMed Web of Science ®Google Scholar
• Lee C, Ramsey-Goldman R. Osteoporosis in systemic lupus erythematosus mechanisms. Rheum Dis Clin North Am. 2005;31(2):363–385.
   PubMed Web of Science ®Google Scholar
• Almehed K, Forsblad d’Elia H, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford). 2007;46(7):1185–1190.
   PubMed Web of Science ®Google Scholar
• Lakshminarayanan S, Walsh S, Mohanraj M, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102–108.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying SK, To CH, et al. Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone. 2008;43(2):327–331.
   PubMed Web of Science ®Google Scholar
• Tang XL, Griffith JF, Qin L, et al. SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. Lupus. 2013;22(11):1162–1168.
   PubMed Web of Science ®Google Scholar
• Kipen Y, Briganti E, Strauss B, et al. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol. 1999;26(2):310–317.
   PubMed Web of Science ®Google Scholar
• Jardinet D, Lefèbvre C, Depresseux G, et al. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford). 2000;39(4):389–392.
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016;22(Suppl 4):1–42.
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–1526.
   PubMed Web of Science ®Google Scholar
• Pharmacovigilance Risk Assessment Committee (PRAC), minutes of the meeting on 07-10 April 2015. [cited 2017 Apr 7]. Available from: www.ema.europa.eu/docs/en_GB/document_library/Minutes/2015/05/WC500187016.pdf
   Google Scholar
• Oxford Centre for Evidence-Based Medicine (OCEBM). Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. 2011. Available from: http://www.cebm.net/index.aspx?o=5653
   Google Scholar